Isarna Therapeutics

Developer of TGF-B inhibitors based therapies for ophthalmic, fibrotic diseases and cancer

placeMunich, Bavaria, Germany calendar_todayFounded 1998 groups3 employees language isarna-therapeutics.com

Registered entities

Innovation

8 patent families (7 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 162 times.

YearFilings
20145
20153
20164
20173
20184
20193
20204
20214
20223

Investor mix

11 investors on record; lead investors include MIG Fonds, Global Chance Fund, Global Asset Fund, S REFIT.

Investor typeCountShare
Venture capital436%
Private equity327%
Accelerator & incubator19%
Other / undisclosed327%
Coming soon